Clinical trials
Completed Lymphoma, B-Cell, Marginal Zone trials in Canada
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
17 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 1 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2015 | 1 |
| 2021 | 1 |
| 2023 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 17 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| NCIC Clinical Trials Group | 3 |
| National Cancer Institute (NCI) | 3 |
| Alliance for Clinical Trials in Oncology | 2 |
| AbbVie (prior sponsor, Abbott) | 1 |
| AstraZeneca | 1 |
| Children's Oncology Group | 1 |
| European Organisation for Research and Treatment of Cancer - EORTC | 1 |
| Janssen Research & Development, LLC | 1 |
| London Health Sciences Centre | 1 |
| Prelude Therapeutics | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lymphoma, B-Cell, Marginal Zone | 17 |
| Lymphoma, Mantle-Cell | 17 |
| Lymphoma, Follicular | 16 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 15 |
| Lymphoma, Large B-Cell, Diffuse | 12 |
| Lymphoma, Non-Hodgkin | 12 |
| Burkitt Lymphoma | 11 |
| Lymphoma, Large-Cell, Immunoblastic | 11 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 11 |
| Waldenstrom Macroglobulinemia | 10 |
Trials
Showing 1 to 17 of 17. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.